G LP ‐1 enhances β‐cell response to protein ingestion and bariatric surgery amplifies it
Obesity · 2025
DOI: 10.1002/oby.24182 ↗Kurz gefasst
Fachartikel in der Zeitschrift Obesity, 2025. Verfasst von Maria Rayas und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, University of Texas Health at San Antonio, San Antonio, Texas, USA. Hauptthemen laut MEDLINE: Insulin-Secreting Cells, Glucagon-Like Peptide 1, Insulin, Blood Glucose. Die Arbeit nennt 41 Literaturangaben. Gefördert von: NCATS NIH HHS, NIDDK NIH HHS, European Union's Horizon 2020 Research and Innovation Programme for the project Stratification of Obesity Phenotypes to Optimize Future Obesity Therapy (SOPHIA).
Abstract (Originalsprache)
Objective
The glycemic‐independent actions of glucagon‐like peptide‐1 (GLP‐1) in the prandial state in humans are unknown. We examined the contribution of GLP‐1 to β‐cell secretory response (primary endpoint) and glucose metabolism during protein ingestion under basal glycemia, as well as whether these responses are affected by rerouted gut after gastric bypass (GB) or sleeve gastrectomy (SG).
Methods
Insulin secretion rate (ISR) and glucose fluxes during a 50‐g oral protein load were compared among 10 nondiabetic individuals with GB, 9 with SG, and 7 non‐operated controls (CN), with and without intravenous infusion of exendin(9‐39) (Ex‐9), a GLP‐1 receptor (GLP‐1R) antagonist.
Results
Blocking GLP‐1R increased glucose before and after protein ingestion and decreased β‐cell sensitivity to glucose in the first 30 min of protein ingestion in all three groups ( p < 0.05). Reduction in the premeal ISR by Ex‐9 infusion was only observed in CN, whereas diminished prandial ISR 3h by GLP‐1R blockade was only observed in GB and SG ( p < 0.05 for interaction). GLP‐1R blockade enhanced post‐protein insulin action in GB and SG, but not in CN, and exaggerated endogenous glucose production only GB ( p < 0.05 for interaction).
Conclusions
These findings are consistent with both pancreatic and extra‐pancreatic roles for GLP‐1 during protein ingestion in humans that are exaggerated by bariatric surgery. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, University of Texas Health at San Antonio, San Antonio, Texas, USA.
- Cardiometabolic Risk Unit, CNR Institute of Clinical Physiology, Pisa, Italy.
- Division of Diabetes, Department of Medicine, University of Texas Health at San Antonio, San Antonio, Texas, USA.
- Department of Surgery, University of Texas Health at San Antonio, San Antonio, Texas, USA.
- South Texas Veterans Health Care System, Audie Murphy Hospital, San Antonio, Texas, USA.
ORCID-Profile: Amalia Gastaldelli, Marzieh Salehi
Förderung
- NCATS NIH HHS
- NIDDK NIH HHS
- European Union's Horizon 2020 Research and Innovation Programme for the project Stratification of Obesity Phenotypes to Optimize Future Obesity Therapy (SOPHIA)
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Center for Advancing Translational Sciences
- Sophia University
Zitieren
APA
Rayas, M., Pezzica, S., Honka, H., Carli, F., Peterson, R., DeFronzo, R., Gastaldelli, A., & Salehi, M. (2025). G LP ‐1 enhances β‐cell response to protein ingestion and bariatric surgery amplifies it. Obesity. https://doi.org/10.1002/oby.24182
Vancouver
Rayas M, Pezzica S, Honka H, Carli F, Peterson R, DeFronzo R, et al. G LP ‐1 enhances β‐cell response to protein ingestion and bariatric surgery amplifies it. Obesity. 2025. doi:10.1002/oby.24182
BibTeX
@article{Rayas2025,
author = {Rayas, Maria and Pezzica, Samantha and Honka, Henri and Carli, Fabrizia and Peterson, Richard and DeFronzo, Ralph and Gastaldelli, Amalia and Salehi, Marzieh},
title = {G LP ‐1 enhances β‐cell response to protein ingestion and bariatric surgery amplifies it},
journal = {Obesity},
year = {2025},
doi = {10.1002/oby.24182}
}
EUVIMED